Publications

Showing 51–60 of 75 results from Publika

Chen HH, Schirger JA, Cataliotti A, Burnett JC (2006)
Intact acute cardiorenal and humoral responsiveness following chronic subcutaneous administration of the cardiac peptide BNP in experimental heart failure
Eur J Heart Fail, 8 (7), 681-6
PubMed 16459135 DOI 10.1016/j.ejheart.2005.12.005
Hawkridge AM, Heublein DM, Bergen HR, Cataliotti A, Burnett JC, Muddiman DC (2005)
Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure
Proc Natl Acad Sci U S A, 102 (48), 17442-7
PubMed 16293687 DOI 10.1073/pnas.0508782102
Martin FL, Stevens TL, Cataliotti A, Schirger JA, Borgeson DD, Redfield MM, Luchner A, Burnett JC (2005)
Natriuretic and antialdosterone actions of chronic oral NEP inhibition during progressive congestive heart failure
Kidney Int, 67 (5), 1723-30
PubMed 15840018 DOI 10.1111/j.1523-1755.2005.00269.x
James KD, Cataliotti A, Schirger JA, Plonka S, Burnett JC (2005)
Congestive heart failure: pharmacological agents and the potential of B-type natriuretic Peptide
Curr Med Chem, 12 (12), 1439-47
PubMed 15974994 DOI 10.2174/0929867054020909
Chen HH, Cataliotti A, Schirger JA, Martin FL, Burnett JC (2004)
Equimolar doses of atrial and brain natriuretic peptides and urodilatin have differential renal actions in overt experimental heart failure
Am J Physiol Regul Integr Comp Physiol, 288 (5), R1093-7
PubMed 15627648 DOI 10.1152/ajpregu.00682.2004
Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Giacone G, Cataliotti A, Seminara G, Stancanelli B, Malatino LS (2004)
Prognostic value of echocardiographic indicators of left ventricular systolic function in asymptomatic dialysis patients
J Am Soc Nephrol, 15 (4), 1029-37
PubMed 15034106 DOI 10.1097/01.asn.0000117977.14912.91
Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Giacone G, Stancanelli B, Cataliotti A, Malatino LS (2004)
Left ventricular mass monitoring in the follow-up of dialysis patients: prognostic value of left ventricular hypertrophy progression
Kidney Int, 65 (4), 1492-8
PubMed 15086493 DOI 10.1111/j.1523-1755.2004.00530.x
Panuccio V, Tripepi R, Tripepi G, Mallamaci F, Benedetto FA, Cataliotti A, Bellanuova I, Giacone G, Malatino LS, Zoccali C (2004)
Heart valve calcifications, survival, and cardiovascular risk in hemodialysis patients
Am J Kidney Dis, 43 (3), 479-84
PubMed 14981606 DOI 10.1053/j.ajkd.2003.11.009
Schirger JA, Chen HH, Jougasaki M, Lisy O, Boerrigter G, Cataliotti A, Burnett JC (2003)
Endothelin A receptor antagonism in experimental congestive heart failure results in augmentation of the renin-angiotensin system and sustained sodium retention
Circulation, 109 (2), 249-54
PubMed 14691038 DOI 10.1161/01.CIR.0000109139.69775.EB
Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Parlongo S, Cutrupi S, Iellamo D, Bonanno G, Rapisarda F, Fatuzzo P, Seminara G, Cataliotti A, Malatino LS (2003)
Prospective study of neuropeptide y as an adverse cardiovascular risk factor in end-stage renal disease
J Am Soc Nephrol, 14 (10), 2611-7
PubMed 14514739 DOI 10.1097/01.asn.0000089026.28617.33